Evidence map›Paper›PMID 34094686›Full record

ArticleAmerican journal of cancer research2021

Mitochondrial structural alterations in ovarian cancer patient-derived xenografts resistant to cisplatin.

Francesca Ricci, Alessandro Corbelli, Roberta Affatato, Rosaria Chilà, Michela Chiappa, Laura Brunelli, Robert Fruscio, Roberta Pastorelli, Fabio Fiordaliso, Giovanna Damia

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Francesca RicciLaboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS Via Mario Negri 2, Milan 20156, Italy.
Alessandro CorbelliUnit of Bio-Imaging, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS Via Mario Negri 2, Milan 20156, Italy.
Roberta AffatatoLaboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS Via Mario Negri 2, Milan 20156, Italy.
Rosaria ChilàLaboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS Via Mario Negri 2, Milan 20156, Italy.
Michela ChiappaLaboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS Via Mario Negri 2, Milan 20156, Italy.
Laura BrunelliUnit of Protein and Metabolite Biomarkers, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS Via Mario Negri 2, Milan 20156, Italy.
Robert FruscioClinic of Obstetrics and Gynecology, Department of Medicine and Surgery, University of Milan Bicocca, San Gerardo Hospital Monza 20900, Italy.
Roberta PastorelliUnit of Protein and Metabolite Biomarkers, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS Via Mario Negri 2, Milan 20156, Italy.
Fabio FiordalisoUnit of Bio-Imaging, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS Via Mario Negri 2, Milan 20156, Italy.
Giovanna DamiaLaboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS Via Mario Negri 2, Milan 20156, Italy.
Mario Negri Institute for Pharmacological Research · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondria have attracted attention in cancer research as organelles associated with tumor development and response to therapy. We recently reported acquisition of resistance to cisplatin (DDP) associated with a metabolic rewiring in ovarian cancer patient-derived xenografts (PDXs) models. DDP-resistant PDXs models were obtained mimicking the clinical setting, treating mice bearing sensitive-DDP tumors with multiple cycles of DDP until the development of resistance. To further characterize the metabolic rewiring, the present study focused on tumor mitochondria. We analysed by transmission electron microscopy the mitochondria structure in two models of DDP-resistant and the corresponding DDP-sensitive PDXs and evaluated tumor mDNA content, the expression of genes and proteins involved in mitochondria functionality, and mitochondria fitness-related processes, such as autophagy. We observed a decrease in the number of mitochondria paralleled by an increased volume in DDP-resistant versus DDP-sensitive PDXs. DDP-resistant PDXs presented a higher percentage of damaged mitochondria, in particular of type 2 (concave-shape), and type 3 (cristolysis) damage. We found no difference in the mDNA content, and the expression of genes involved in mitochondrial biogenesis was similar between the sensitive and resistant PDXs. An upregulation of some genes involved in mitochondrial fitness in DDP-R versus DDP-S PDXs was observed. At protein level, no difference in the expression of proteins involved in mitochondrial function and biogenesis, and in autophagy/mitophagy was found. We here reported that the acquisition of DDP resistance is associated with morphological alterations in mitochondria, even if we couldn't find any dysregulation in the studied genes/proteins that could explain the observed differences.

Indexed as

Mitochondriaplatinum resistance and ovarian carcinoma

Identifiers

PMID34094686
PMCPMC8167697
OpenAlexW3168166910

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.